GlassScriptPhysician profile
David P Shu
NPI 1285675355
$3,313.81
in general payments reported to CMS, 2019-2025
17 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.87 · 2022: $51.12 · 2023: $353 · 2024: $932 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,246.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,482.80 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $335.60 | 2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $330.16 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $210.10 | 2024-2025 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $164.40 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
| Gilead Sciences, INC. | $112.36 | 2025 | |
| Exact Sciences Corporation | $104.49 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $96.24 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $95.11 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $60.74 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.12 | 2025 | Jardiance |
| Corium, LLC | $34.21 | 2022 | |
| Alnylam Pharmaceuticals INC. | $33.41 | 2025 | Givlaari |
| Agios Pharmaceuticals, INC. | $32.73 | 2025 | Pyrukynd |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.43 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $16.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.